These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30745021)

  • 21. Complex measures and indices for clinical research compared with simple patient questionnaires to assess function, pain, and global estimates as rheumatology "vital signs" for usual clinical care.
    Pincus T; Bergman MJ; Maclean R; Yazici Y
    Rheum Dis Clin North Am; 2009 Nov; 35(4):779-86, ix. PubMed ID: 19962622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic and prognostic role of renal histopathology in rheumatic diseases.
    Saccon F; Gatto M; Larosa M; Ometto F; Felicetti M; Padoan R; Zen M
    Reumatismo; 2018 Oct; 70(3):165-177. PubMed ID: 30282442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The responsiveness of generic quality of life instruments in rheumatic diseases. A systematic review of randomized controlled trials.
    Ortiz Z; Shea B; Garcia Dieguez M; Boers M; Tugwell P; Boonen A; Wells G
    J Rheumatol; 1999 Jan; 26(1):210-6. PubMed ID: 9918266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group.
    Klokker L; Tugwell P; Furst DE; Devoe D; Williamson P; Terwee CB; Suarez-Almazor ME; Strand V; Woodworth T; Leong AL; Goel N; Boers M; Brooks PM; Simon LS; Christensen R
    J Rheumatol; 2017 Dec; 44(12):1916-1919. PubMed ID: 27744393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modern psychometrics applied in rheumatology--a systematic review.
    Siemons L; Ten Klooster PM; Taal E; Glas CA; Van de Laar MA
    BMC Musculoskelet Disord; 2012 Oct; 13():216. PubMed ID: 23114105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI.
    Gaujoux-Viala C; Mouterde G; Baillet A; Claudepierre P; Fautrel B; Le Loët X; Maillefert JF
    Joint Bone Spine; 2012 Mar; 79(2):149-55. PubMed ID: 21680221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The accuracy of administrative data diagnoses of systemic autoimmune rheumatic diseases.
    Bernatsky S; Linehan T; Hanly JG
    J Rheumatol; 2011 Aug; 38(8):1612-6. PubMed ID: 21532057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The changing spectrum of rheumatic disease in human immunodeficiency virus infection.
    Reveille JD
    Semin Arthritis Rheum; 2000 Dec; 30(3):147-66. PubMed ID: 11124280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials.
    Klokker L; Berthelsen DB; Woodworth T; Andersen KM; Furst DE; Devoe D; Williamson PR; Suarez-Almazor ME; Strand V; Leong AL; Goel N; Boers M; Brooks PM; March L; Sloan VS; Tugwell P; Simon LS; Christensen R
    J Rheumatol; 2019 Sep; 46(9):1173-1178. PubMed ID: 31043547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. OMERACT: an international initiative to improve outcome measurement in rheumatology.
    Boers M; Brooks P; Simon LS; Strand V; Tugwell P
    Clin Exp Rheumatol; 2005; 23(5 Suppl 39):S10-3. PubMed ID: 16273779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. OMERACT Definitions for Ultrasonographic Pathologies and Elementary Lesions of Rheumatic Disorders 15 Years On.
    Bruyn GA; Iagnocco A; Naredo E; Balint PV; Gutierrez M; Hammer HB; Collado P; Filippou G; Schmidt WA; Jousse-Joulin S; Mandl P; Conaghan PG; Wakefield RJ; Keen HI; Terslev L; D'Agostino MA;
    J Rheumatol; 2019 Oct; 46(10):1388-1393. PubMed ID: 30709946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic utility of automated indirect immunofluorescence compared to manual indirect immunofluorescence for anti-nuclear antibodies in patients with systemic rheumatic diseases: A systematic review and meta-analysis.
    Kim J; Lee W; Kim GT; Kim HS; Ock S; Kim IS; Jeong S
    Semin Arthritis Rheum; 2019 Feb; 48(4):728-735. PubMed ID: 29706242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management.
    Giacomelli R; Afeltra A; Alunno A; Baldini C; Bartoloni-Bocci E; Berardicurti O; Carubbi F; Cauli A; Cervera R; Ciccia F; Cipriani P; Conti F; De Vita S; Di Benedetto P; Doria A; Drosos AA; Favalli EG; Gandolfo S; Gatto M; Grembiale RD; Liakouli V; Lories R; Lubrano E; Lunardi C; Margiotta DPE; Massaro L; Meroni P; Minniti A; Navarini L; Pendolino M; Perosa F; Pers JO; Prete M; Priori R; Puppo F; Quartuccio L; Ruffatti A; Ruscitti P; Russo B; Sarzi-Puttini P; Shoenfeld Y; Somarakis GA; Spinelli FR; Tinazzi E; Triolo G; Ursini F; Valentini G; Valesini G; Vettori S; Vitali C; Tzioufas AG
    Autoimmun Rev; 2017 Sep; 16(9):911-924. PubMed ID: 28705780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health outcomes of pediatric rheumatic diseases.
    Luca NJ; Feldman BM
    Best Pract Res Clin Rheumatol; 2014 Apr; 28(2):331-50. PubMed ID: 24974066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0.
    Boers M; Kirwan JR; Gossec L; Conaghan PG; D'Agostino MA; Bingham CO; Brooks PM; Landewé R; March L; Simon L; Singh JA; Strand V; Wells GA; Tugwell P
    J Rheumatol; 2014 May; 41(5):1025-30. PubMed ID: 24584913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Laboratory tests in the diagnosis and follow-up of pediatric rheumatic diseases: an update.
    Breda L; Nozzi M; De Sanctis S; Chiarelli F
    Semin Arthritis Rheum; 2010 Aug; 40(1):53-72. PubMed ID: 19246077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recommendations for the Involvement of Patient Research Partners (PRP) in OMERACT Working Groups. A Report from the OMERACT 2014 Working Group on PRP.
    Cheung PP; de Wit M; Bingham CO; Kirwan JR; Leong A; March LM; Montie P; Scholte-Voshaar M; Gossec L
    J Rheumatol; 2016 Jan; 43(1):187-93. PubMed ID: 25877496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative.
    Højgaard P; Klokker L; Orbai AM; Holmsted K; Bartels EM; Leung YY; Goel N; de Wit M; Gladman DD; Mease P; Dreyer L; Kristensen LE; FitzGerald O; Tillett W; Gossec L; Helliwell P; Strand V; Ogdie A; Terwee CB; Christensen R
    Semin Arthritis Rheum; 2018 Apr; 47(5):654-665. PubMed ID: 29037523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validity.
    Tugwell P; Boers M; D'Agostino MA; Beaton D; Boonen A; Bingham CO; Choy E; Conaghan PG; Dougados M; Duarte C; Furst DE; Guillemin F; Gossec L; Heiberg T; van der Heijde DM; Hewlett S; Kirwan JR; Kvien TK; Landewé RB; Mease PJ; Østergaard M; Simon L; Singh JA; Strand V; Wells G
    J Rheumatol; 2014 May; 41(5):1000-4. PubMed ID: 24692531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0.
    Boers M; Kirwan JR; Wells G; Beaton D; Gossec L; d'Agostino MA; Conaghan PG; Bingham CO; Brooks P; Landewé R; March L; Simon LS; Singh JA; Strand V; Tugwell P
    J Clin Epidemiol; 2014 Jul; 67(7):745-53. PubMed ID: 24582946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.